Proteomics International Laboratories has employed business veteran Dr James Williams as a non-executive director in a boardroom boost geared toward serving to information the corporate’s pathway in direction of commercialising its predictive diagnostics instruments.
Dr Williams, a seasoned determine and entrepreneur within the life sciences sector, has greater than 25 years of expertise as chief government officer, chief know-how director and director inside a number of completely different biotech corporations.
Dr James Williams, a biotech business veteran, has been appointed to the board of Proteomics International Laboratories as a non-executive director.
Proteomics says he’ll add invaluable expertise to the board after taking part in a key position within the improvement of 5 United States Food and Drug Administration (FDA)-approved medicine and medical units. He was additionally the co-discoverer of the lead remedy for Dimerix, which is presently conducting phase-three scientific trials for persistent kidney illness.
‘James brings industry-specific skills and a proven record of commercialisation experience to strengthen our Board at a pivotal stage of our company’s improvement.’
Proteomics International Laboratories managing director Dr Richard Lipscombe
Dr Williams is the present Health Translation Group chief government officer and holds board positions on the Perron Institute for Neurological and Translational Science in Perth and Western Australian-based sustainable crop safety options firm, Demagtech. His earlier roles embrace co-founding early-stage enterprise capital agency Yuuwa Capital and contributing to a number of Australian Government advisory committees.
Proteomics International Laboratories managing director Dr Richard Lipscombe mentioned: “James brings industry-specific skills and a proven record of commercialisation experience to strengthen our Board at a pivotal stage of our company’s development and his wealth of industry-specific knowledge, especially in the chronic kidney disease space, will be invaluable. With operational insights from an accomplished entrepreneur and investor we look forward to leveraging his experience in the next phase of Proteomics International’s growth”.
Dr Williams believes Proteomics is poised for “substantial growth”, significantly by the corporate’s modern diagnostic checks for circumstances similar to diabetic kidney illness, endometriosis and esophageal most cancers and their potential to meet unfilled medical wants.
The discipline of proteomics revolves across the large-scale research of proteins and the corporate is presently centered on the event of its “PromarkerD” predictive diagnostic instrument that may detect persistent kidney illness in sort 2 diabetes sufferers.
The firm just lately revealed at an Australasian diabetes convention in Perth that its testing has now confirmed glorious predictive qualities in detecting the opportunity of future renal decline in sort 1 sufferers, marking a big breakthrough for its know-how. Management says the checks point out that PromarkerD is no less than pretty much as good at predicting renal decline in sort 1 sufferers as it’s for these dwelling with the sort 2 model of the widespread illness.
